A J Heslegrave - JoVE Visualize

Showing results (1-10 of 4) with videos related to

Pageof 1

Sort By:

The European Journal of Neuroscience|March 6, 2002

Nitric oxide-dependent damage to neuronal mitochondria involves the NMDA receptorV C Stewart, A J Heslegrave, G C Brown, et al.

Human Molecular Genetics|August 15, 2019

Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1XA Kagiava, J Richter, C Tryfonos, et al.

Translational Psychiatry|November 16, 2016

A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathologyR W Paterson, W E Heywood, A J Heslegrave, et al.

Journal of Internal Medicine|May 22, 2021

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's diseaseD O T Alawode, A J Heslegrave, N J Ashton, et al.

Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:

Pageof 1

The European Journal of Neuroscience|March 6, 2002

Nitric oxide-dependent damage to neuronal mitochondria involves the NMDA receptorV C Stewart, A J Heslegrave, G C Brown, et al.

Human Molecular Genetics|August 15, 2019

Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1XA Kagiava, J Richter, C Tryfonos, et al.

Translational Psychiatry|November 16, 2016

A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathologyR W Paterson, W E Heywood, A J Heslegrave, et al.

Journal of Internal Medicine|May 22, 2021

Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's diseaseD O T Alawode, A J Heslegrave, N J Ashton, et al.

Pageof 1